• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Nemus Bioscience's Synthetic CBD Improves Ocular Absorption

August 7, 2017

 (Image Credit - Franko Zeitz)

This morning, Nemus Bioscience (OTC:NMUS) announced that the company's topical CBD-analogue (NB2222) was able to penetrate multiple compartments of the eye, demonstrating significantly improved ocular absorption versus naturally derived CBD. 


This pre-clinical research was conducted by the company's R&D partner, the University of Mississippi, and the results will be presented at the American Association of Pharmaceutical Scientists meeting in San Diego this November. 


Going forward, Nemus and the University of Mississippi will be continuing to test various formulations of NB2222 and will be progressing to test the drug in animal models of ocular disease. 


Dr. Soumyajit Majumdar, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy and lead scientist of the Nemus ophthalmic platform had this to say about the results: 


 "Topical NB2222 was able to penetrate multiple compartments of the eye including the retina-choroid and vitreous humor, tissues that help maintain optic nerve function. We did not see this type of ocular bioavailability with CBD derived from the plant and administered under identical testing conditions. We look forward to working with Nemus to advance this novel bio-engineered molecule into advanced formulation testing as well as studies examining specific animal models of ocular disease ahead of human studies."


Nemus' CEO and Chief Medical Officer, Brian Murphy, MD, MBA also expressed optimism regarding the company's ocular platform: 


"The development of a comprehensive, multi-cannabinoid drug platform for ophthalmic uses is an important developmental goal for Nemus. Having access to both the prodrug of THC (NB1111) and the analogue of CBD (NB2222) could potentially add therapeutic indications to our proprietary ocular medicine platform, including dry eye syndrome, uveitis, and glaucoma in the anterior compartment of the eye, as well as macular degeneration and diabetic retinopathy in the posterior compartment."


Market Reaction 

In early trading Monday, shares of Nemus Bioscience are falling roughly 2% on light trading volume. We'll be watching to see how the markets continue to digest these optimistic results from early stage research.


Be sure to check out Nemus' marijuana stock profile to learn more and view a custom stock chart. 
To stay up to date with developments in the cannabinoid biotech space be sure to subscribe to our free cannabinoid biotech & pharma email newsletter if you haven't already. 
Don't be a stranger, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram





Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.